BridgeBio Oncology Therapeutics Inc. (BBOT) vs SAB Biotherapeutics, Inc. (SABS)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and SAB Biotherapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.54HealthcareDelayed quote: Oct 6, 2026, 1:54 PM EDT
SABS
SAB Biotherapeutics, Inc.
$2.96HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — BBOT vs SABS
growth of $100 · dividends reinvested · last 3yBBOT -64.7% (-29.3%/yr)SABS -42.9% (-17.0%/yr)SABS compounded faster over this window
BBOT SABS
BBOT vs SABS: by the numbers
- •BBOT is the larger company ($283M vs $269M market cap).
Metrics side by side
Valuation
| Metric | BBOT | SABS |
|---|---|---|
| P/B ratio | 0.88 | 1.25 |
Profitability
| Metric | BBOT | SABS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -56.36% | -5.95% |
| ROIC | -61.10% | -31.62% |
Growth (annualized)
| Metric | BBOT | SABS |
|---|---|---|
| EPS CAGR (5Y) | N/A | -50.57% |
| Total return CAGR (5Y) | N/A | -50.16% |
Go deeper
Dig into the metrics
BridgeBio Oncology Therapeutics ROESAB Biotherapeutics ROEBridgeBio Oncology Therapeutics operating marginSAB Biotherapeutics operating marginBridgeBio Oncology Therapeutics revenue growthSAB Biotherapeutics revenue growthBridgeBio Oncology Therapeutics free cash flowSAB Biotherapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.